Q-omics provides the consensus-scored FAHD2B profile across patient tissues and cancer cell-line models. FAHD2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, FAHD2B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FAHD2B RNA expression shows 17,015 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KIRC, and ACC as cancer lineages where FAHD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAHD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAHD2B survival associations across molecular data types. FAHD2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAHD2B RNA expression–survival associations across cancer types. High FAHD2B expression shows unfavorable associations in LGG and KIRP, but favorable associations in BRCA, READ, UVM and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for FAHD2B RNA expression.
This table summarizes FAHD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAHD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAHD2B shows lower tumor expression in KIRC, THCA, KIRP, UCEC and KICH and higher tumor expression in CHOL. The KIRC box plot shows higher FAHD2B RNA expression in normal versus tumor tissue (log2 FC = −1.194, t-test p < 0.001).
This table shows molecular features associated with FAHD2B in patient tissues and cancer cell lines. In patient samples, FAHD2B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAHD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
